Skip to main content
AAN.com
Brief Communications
April 11, 2005

Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale

April 12, 2005 issue
64 (7) 1261-1262

Abstract

Measuring the severity of neurologic dysfunction in patients with inherited ataxias, including Friedreich ataxia (FA), is difficult because of the variable rate of progression, the variable age at onset and the variety of neural systems that may be affected. The authors discuss the problems related to rating scales in the ataxias, report a neurologic rating scale for FA, and demonstrate acceptable interrater reliability of the instrument.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (appendix_1.doc)
File (e1.doc)
File (e2.doc)
File (e3.doc)

References

1.
Storey E, Tuck K, Hughes A, Churchyard A. Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS). Mov Disord 2004;19:190–192.
2.
Filla A, De Michele, Orefice G et al. A double-blind cross-over trial of amantadine hydrochloride in Friedreich’s ataxia. Can J Neurol Sci 1993;20:52–55.
3.
Pourcher E, Barbeau A. Field testing of an ataxia scoring and staging system. Can J Neurol Sci 1980;7:339–344.
4.
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420–428.
5.
Lou JS, Goldfarb LG, McShane L et al. Use of buspirone for treatment of cerebellar ataxia. Arch Neurol 1995;52:982–988.
6.
Wessel K, Huss G-P, Bruckmann H, Kompf D. Follow-up of neurophysiological tests and CT in late-onset cerebellar ataxia and multiple system atrophy. J Neurol 1993;240:168–176.
7.
Trouillas P, Brudon F, Adeline P. Improvement of cerebellar ataxia with levo-rotatory form of 5-hydroxytryptophan. A double-blind cross-over study with quantified data processing. Arch Neurol 1988;45:1217–1222.
8.
Fillyaw MJ, Badger GJ, Bradley WG et al. Quantitative measures of neurological function in chronic neuromuscular diseases and ataxia. J Neurol Sci 1989;92:17–36.

Information & Authors

Information

Published In

Neurology®
Volume 64Number 7April 12, 2005
Pages: 1261-1262
PubMed: 15824358

Publication History

Published online: April 11, 2005
Published in print: April 12, 2005

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

S. H. Subramony, MD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
W. May, PhD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
D. Lynch, MD, PhD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
C. Gomez, MD, PhD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
K. Fischbeck, MD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
M. Hallett, MD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
P. Taylor, MD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
R. Wilson, MD, PhD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
T. Ashizawa, MD
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.
for the Cooperative Ataxia Group
From the Departments of Neurology (Dr. Subramony) and Preventive Medicine (Dr. May), University of Mississippi Medical Center, Jackson; Department of Neurology (Dr. Lynch), Children’s Hospital of Pennsylvania, Philadelphia; Department of Neurology (Dr. Gomez), University of Minnesota, Minneapolis; Neurogenetics Branch (Dr. Fischbeck), NINDS (Dr. Hallett), NIH, Bethesda, MD; Departments of Neurology (Dr. Taylor) and Pathology (Dr. Wilson), University of Pennsylvania, Philadelphia; Department of Neurology (Dr. Ashizawa), University of Texas Medical Branch, Galveston.

Notes

Address correspondence and reprint requests to Dr. S.H. Subramony, Department of Neurology, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS 39216; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Friedreich ataxia, Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, (107-125), (2025).https://doi.org/10.1016/B978-0-443-19176-3.00041-8
    Crossref
  2. Introductory Chapter: Insights into Ataxia, Ataxia - Practice Essentials and Interventions, (2024).https://doi.org/10.5772/intechopen.113755
    Crossref
  3. Friedreich Ataxia Caregiver-Reported Health Index, Neurology Clinical Practice, 14, 3, (2024)./doi/10.1212/CPJ.0000000000200300
    Abstract
  4. Development and validation of TreatHSP-QoL: a patient-reported outcome measure for health-related quality of life in hereditary spastic paraplegia, Orphanet Journal of Rare Diseases, 19, 1, (2024).https://doi.org/10.1186/s13023-023-03012-w
    Crossref
  5. Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data, Expert Opinion on Pharmacotherapy, 25, 5, (529-539), (2024).https://doi.org/10.1080/14656566.2024.2343782
    Crossref
  6. Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses, Molecular Genetics and Metabolism, 142, 3, (108512), (2024).https://doi.org/10.1016/j.ymgme.2024.108512
    Crossref
  7. Practical recommendations for the clinical evaluation of patients with hereditary ataxia and hereditary spastic paraplegia, Neurología (English Edition), 39, 6, (515-522), (2024).https://doi.org/10.1016/j.nrleng.2022.02.002
    Crossref
  8. Guía práctica de evaluación de pacientes con ataxias y paraparesias espásticas hereditarias en consulta, Neurología, 39, 6, (515-522), (2024).https://doi.org/10.1016/j.nrl.2022.02.004
    Crossref
  9. Clinical stage and plasma neurofilament concentration in adults with Friedreich ataxia, Heliyon, 10, 1, (e23347), (2024).https://doi.org/10.1016/j.heliyon.2023.e23347
    Crossref
  10. GAA-FGF14 disease: defining its frequency, molecular basis, and 4-aminopyridine response in a large downbeat nystagmus cohort, eBioMedicine, 102, (105076), (2024).https://doi.org/10.1016/j.ebiom.2024.105076
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share